Saturday, October 31, 2026

GBP/EUR Over 1% Up In The Last 10 Sessions

ViaNews Editorial Team

December 1, 2023

GBP/EUR Over 1% Up In The Last 10 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 1.36% for the last 10 sessions. At 07:10 EST on Friday, 1 December, GBP/EUR (GBPEUR) is $1.16.

GBP/EUR's yearly highs and lows, it's 4.104% up from its 52-week low and 1.512% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was 0.16%, 0.03%, and 0.19%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.16% (last week), 0.20% (last month), and 0.19% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be oversold (<=20).

News about

  • Eur/usd price analysis: the key contention level is seen at 1.0930. According to FXStreet on Thursday, 30 November, "The EUR/USD pair trades with modest intraday losses during the early European session on Thursday. ", " From the technical perspective, EUR/USD maintains a positive vibe as the major holds above the 50- and 100-hour Exponential Moving Averages (EMA) on the four-hour chart. "
  • Eur/usd slipping back as the 1.1000 handle begins to look more like a ceiling that a goal. According to FXStreet on Wednesday, 29 November, "The Euro has climbed over 5% against the US Dollar since October's swing low into 1.0450, and the EUR/USD is holding in the green for the year, but 2023's mid-year peak at 1.1275 is weighing on the long-term trend as the pair gets weighed down near 1.1000 with technical indicators leaning into overbought territory.", "The EUR/USD has been on a steady climb ever since the Euro crashed through the 200-day Simple Moving Average (SMA) near 1.0800, and the pair is running into technical resistance from the 1.1000 handle."
  • Eur/usd maintains its position above 1.1000 ahead of Spain, Germany CPI data. According to FXStreet on Wednesday, 29 November, "The EUR/USD pair is benefiting from the softer US Dollar (USD), which is influenced by a less hawkish stance from the US Federal Reserve (Fed)."
  • Eur/usd forex signal: head and shoulders pattern forms - 29 November 2023. According to DailyForex on Wednesday, 29 November, "The EUR/USD will be in the spotlight on Wednesday as the US publishes the second estimate of Q3 GDP data. ", "Forex Brokers We Recommend in Your Region See full brokers list 1 Read full review Get Started BrokerGeoLists.push({type:'ReviewsNonPartner',id:'horizontal-top-5',size:5,fullReviewText:`Read full review`,getStartedText:`Get Started`,readReviewText:`Review`});Bearish viewSell the EUR/USD pair and set a take-profit at 1.0900."
  • According to FXStreet on Thursday, 30 November, "At the time of writing, the EUR/USD is dropping 0.05% on the day to trade at 1.0971."

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com